PrIMAVeRa partners share latest vaccine research at 6th ESCMID Conference on Vaccines
- europevaccine
- Oct 13
- 2 min read
13 September 2025
From 10‑13 September 2025, the PrIMAVeRa team participated in the 6th ESCMID Conference on Vaccines: “From Development to Real‑World Clinical Practice & Global Health” in Lisbon, Portugal.
Prof. Julie Robotham presented on ‘Modelling in AMR for Vaccine Value Assessment’. The session, chaired by the ESCMID president Prof Robert Skov, provided an overview of the challenge Antimicrobial Resistance poses and how vaccines may help us tackle it and particularly the advances that PrIMAVeRa is helping to achieve.
Conference participants showed strong interest in PrIMAVeRa’s approach to leveraging real‑world evidence (RWE) to inform vaccine policy, especially its use of modelling to estimate population‑level impacts. The team’s findings on cost‑effectiveness and the highlighting of key uncertainties and important questions that remain also prompted lively discussion.
PrIMAVeRa partners expressed that the conference was an excellent forum for feedback on the translation of project outputs to inform policy and practice. The insights gained will feed into upcoming work packages, from key considerations within the cost-effectiveness model design to how best to communicate and disseminate project findings to generate maximal impact.
Prof. Robotham stated that “The opportunity to share the important and state-of-the-art research undertaken by the PrIMAVeRa consortium at ESCMID Vaccines facilitated highly beneficial engagement with world-leading and multidisciplinary experts from across the entire vaccine development pipeline.”
This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and
innovation programme and EFPIA. www.imi.europa.eu
This communication reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
